Human Anti-HIV-1 Env Recombinant Antibody (clone PGDM1400) (CAT#: PABL-151)

Figure 1 Human Anti-HIV-1 Env Recombinant Antibody (PABL-151) in SDS-PAGE

SDS-PAGE analysis of PABL-151 in β-mercaptoethanol-reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result, the different reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

The purity of PABL-151 was greater than 95% as determined by SDS-PAGE.

Figure 2 Human Anti-HIV-1 Env Recombinant Antibody (PABL-151) in SEC-HPLC

The purity of PABL-151 was 98.9773% as determined by SEC-HPLC.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Human Anti-HIV-1 Env Recombinant Antibody (PABL-151) in WB

Western blot analysis of PABL-151 was performed by loading recombinant HIV-1 [HIV-1/Clade B/C (CN54)] gp120 protein, (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a NC membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-151 and HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)

Figure 4 Human Anti-HIV-1 Env Recombinant Antibody (PABL-151) in ELISA

ELISA analysis of PABL-151 was performed by coating with recombinant HIV-1 [HIV-1/Clade B/C (CN54)] gp120 protein, (His tag). Then blocked with BSA and incubated with PABL-151. The HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.